Get startedLog in
    Picture of Kenvue logo

    KVUE — Kenvue News Story

    0.000.00%
    us flag iconLast trade - 00:00
    Consumer DefensivesBalancedLarge CapSuper Stock
    All News

    Brief: Kenvue Says FDA Has Granted Tylenol Three-Year Exclusivity For New OTC Formulation

    Picture of Kenvue logoKenvue
    24/07/2026 19:03
    BRIEF-Kenvue Says FDA Has Granted Tylenol Three-Year Exclusivity For New OTC Formulation
    July 24 (Reuters) - Kenvue Inc KVUE.N:
    • FDA APPROVES TYLENOL® WITH NAPROXEN, THE FIRST AND ONLY OVER-THE-COUNTER FIXED-DOSE COMBINATION OF ACETAMINOPHEN (650 MG) AND NAPROXEN SODIUM (220 MG)
    • KENVUE - FDA GRANTS TYLENOL THREE-YEAR EXCLUSIVITY FOR NEW OTC FORMULATION
    • KENVUE - TYLENOL WITH NAPROXEN TO BE AVAILABLE SOON AT MAJOR U.S. RETAILERS

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kenvue

    See all news